Edna Chow Maneval

2.6k total citations · 1 hit paper
41 papers, 1.4k citations indexed

About

Edna Chow Maneval is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Edna Chow Maneval has authored 41 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Pulmonary and Respiratory Medicine, 25 papers in Oncology and 16 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Edna Chow Maneval's work include Prostate Cancer Treatment and Research (20 papers), Radiopharmaceutical Chemistry and Applications (16 papers) and Lung Cancer Treatments and Mutations (12 papers). Edna Chow Maneval is often cited by papers focused on Prostate Cancer Treatment and Research (20 papers), Radiopharmaceutical Chemistry and Applications (16 papers) and Lung Cancer Treatments and Mutations (12 papers). Edna Chow Maneval collaborates with scholars based in United States, Netherlands and Switzerland. Edna Chow Maneval's co-authors include Isan Chen, Jeffrey H. Hager, Nhin Lu, Jing Qian, Dan Brigham, John Sensintaffar, Gang Shao, James D. Joseph, Beatrice Darimont and Dana E. Rathkopf and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Edna Chow Maneval

39 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509

2013 455 citations James D. Joseph, Nhin Lu et al. Cancer Discovery profile →

Peers

Countries citing papers authored by Edna Chow Maneval

Since Specialization

Citations

This map shows the geographic impact of Edna Chow Maneval's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edna Chow Maneval with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edna Chow Maneval more than expected).

Fields of papers citing papers by Edna Chow Maneval

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edna Chow Maneval. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edna Chow Maneval. The network helps show where Edna Chow Maneval may publish in the future.

Co-authorship network of co-authors of Edna Chow Maneval

This figure shows the co-authorship network connecting the top 25 collaborators of Edna Chow Maneval. A scholar is included among the top collaborators of Edna Chow Maneval based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edna Chow Maneval. Edna Chow Maneval is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	62 (PB050): ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, demonstrates best-in-class properties against Exon 20 insertions and other atypical EGFR mutations 2024 ·European Journal of Cancer ·Melissa R. Junttila, Claire E. Repellin, (unknown), Jason E. Long, Lidia Sambucetti, Patricia L. Ashley, Gabriele Andreatta, Jong Sam Baik, Sumeet Salaniwal, Chrystelle Colas, Atocha Romero, Liliana Soroceanu, Rupal Patel, Edna Chow Maneval, Pratik S. Multani, Anneleen Daemen, Lori S. Friedman	2
2	1333P A global phase 1b study of ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, in patients with advanced solid tumors harboring EGFR Exon 20 or HER2 alterations 2023 ·Annals of Oncology ·Min Hee Hong, Alexander I. Spira, Ki Hyeong Lee, (unknown), (unknown), Byoung Yong Shim, JS Lee, (unknown), S-W. Kim, Adnan Khattak, (unknown), Rongda Xu, (unknown), Eric A. Ariazi, Anneleen Daemen, Edna Chow Maneval, Pratik S. Multani, Roopal Patel, M-J. Ahn	5
3	The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer 2022 ·Breast Cancer Research and Treatment ·Aditya Bardia, Ingrid A. Mayer, Eric P. Winer, Hannah M. Linden, X. Cynthia, Barbara A. Parker, Meritxell Bellet, Carlos L. Arteaga, Sravanthi Cheeti, Mary Gates, Ching‐Wei Chang, Jill Fredrickson, Jill M. Spoerke, Heather M. Moore, Jennifer M. Giltnane, Lori S. Friedman, Edna Chow Maneval, Iris T. Chan, Komal Jhaveri	14
4	Initial results from a phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with nab-paclitaxel in patients with advanced solid tumors. 2021 ·Journal of Clinical Oncology ·(unknown), Anthony W. Tolcher, Shivaani Kummar, Manish R. Patel, Alexander I. Spira, (unknown), (unknown), Rongda Xu, Ann Johnson, Anneleen Daemen, Pratik S. Multani, Edna Chow Maneval, Pamela N. Münster	1
5	PDCT-13. ENTRECTINIB IN CHILDREN AND ADOLESCENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS INCLUDING PRIMARY CNS TUMORS 2019 ·Neuro-Oncology ·Giles Robinson, Ami V. Desai, Karen Gauvain, Ellen M. Basu, Kathleen Dorris, Luke Maese, Amit J. Sabnis, Jennifer H. Foster, Suzanne Shusterman, Janet Yoon, Brian Weiss, Mohamed S Abdelbaki, Mufiza Farid‐Kapadia, Georgina Meneses‐Lorente, (unknown), Katherine E. Hutchinson, Guillaume Bergthold, Edna Chow Maneval, Elizabeth Fox, Amar Gajjar	1
6	Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone 2017 ·Clinical Cancer Research ·Dana E. Rathkopf, Emmanuel S. Antonarakis, Neal D. Shore, Ronald Tutrone, Joshi J. Alumkal, Charles J. Ryan, Mansoor N. Saleh, Ralph J. Hauke, Rajesh Bandekar, Edna Chow Maneval, Carla J. de Boer, Margaret K. Yu, Howard I. Scher	64
7	Activity of Entrectinib in a Patient With the First Reported NTRK Fusion in Neuroendocrine Cancer 2017 ·Journal of the National Comprehensive Cancer Network ·Darren Sigal, Marie Tartar, (unknown), (unknown), Patrick J. Foley, David Luo, Jason Christiansen, Zachary Hornby, Edna Chow Maneval, Pratik S. Multani	32
8	TRTH-10. PEDIATRIC PHASE 1/1B STUDY OF ENTRECTINIB IN PATIENTS WITH PRIMARY BRAIN TUMORS, NEUROBLASTOMA, AND NTRK, ROS1, OR ALK FUSIONS 2017 ·Neuro-Oncology ·Sunitha Rangaraju, Gang Li, Jason Christiansen, Zachary Hornby, Pratik S. Multani, (unknown), Edna Chow Maneval	7
9	Abstract CT060: STARTRK-2: A global phase 2, open-label, basket study of entrectinib in patients with locally advanced or metastatic solid tumors harboring TRK, ROS1, or ALK gene fusions 2017 ·Cancer Research ·Alexander Drilon, Kamalesh K. Sankhala, Stephen V. Liu, Byoung Chul Cho, Collin M. Blakely, Cheng Ean Chee, Marwan Fakih, Jonathan Polikoff, Zachary Hornby, (unknown), David Luo, Edna Chow Maneval, Pratik S. Multani, Robert C. Doebele	13
10	Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort 2016 ·European Urology ·Matthew R. Smith, Emmanuel S. Antonarakis, Charles J. Ryan, William L. Berry, Neal D. Shore, Glenn Liu, Joshi J. Alumkal, Celestia S. Higano, Edna Chow Maneval, Rajesh Bandekar, Carla J. de Boer, Margaret K. Yu, Dana E. Rathkopf	100
11	5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study 2015 ·Cancer Management and Research ·J. Randolph Hecht, Edith Mitchell, Takayuki Yoshino, Manfred Welslau, Xun Lin, Edna Chow Maneval, Jolanda Paolini, María José Lechuga, Albrecht Kretzschmar	9
12	Validation of target engagement using 18F-fluoroestradiol PET in patients undergoing therapy with selective estrogen receptor degrader, ARN-810 (GDC-0810) 2015 ·Yingbing Wang, Gary A. Ulaner, H. Charles Manning, Aditya Bardia, Ingrid A. Mayer, Maura N. Dickler, Edna Chow Maneval, Jason S. Lewis, José Baselga, Umar Mahmood	6
13	ARN-509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without prior abiraterone acetate (AA) treatment. 2014 ·Journal of Clinical Oncology ·Dana E. Rathkopf, Emmanuel S. Antonarakis, Neal D. Shore, Ronald Tutrone, Joshi J. Alumkal, Charles J. Ryan, Mansoor N. Saleh, Ralph J. Hauke, Rajesh Bandekar, Edna Chow Maneval, Carla de Boer, Mary B. Todd, Margaret K. Yu, Howard I. Scher	5
14	A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509 breakdown → 2013 ·Cancer Discovery ·James D. Joseph, Nhin Lu, Jing Qian, John Sensintaffar, Gang Shao, Dan Brigham, (unknown), Edna Chow Maneval, Isan Chen, Beatrice Darimont, Jeffrey H. Hager	455
15	Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer 2013 ·Journal of Clinical Oncology ·Dana E. Rathkopf, Michael J. Morris, Josef J. Fox, Daniel C. Danila, Susan F. Slovin, Jeffrey H. Hager, Peter J. Rix, Edna Chow Maneval, Isan Chen, Mithat Gönen, Martin Fleisher, Steven M. Larson, Charles L. Sawyers, Howard I. Scher	204
16	ARN-509 in men with metastatic castration-resistant prostate cancer (mCRPC). 2013 ·Journal of Clinical Oncology ·Dana E. Rathkopf, Emmanuel S. Antonarakis, Neal D. Shore, Ronald Tutrone, Joshi J. Alumkal, Charles J. Ryan, Mansoor N. Saleh, Ralph J. Hauke, Edna Chow Maneval, Howard I. Scher	19
17	A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors 2012 ·Cancer Chemotherapy and Pharmacology ·Stephen Leong, Sabine Eckhardt, Emily Chan, Wells A. Messersmith, Jennifer L. Spratlin, D. Ross Camidge, Sami Diab, Reza Khosravan, Xun Lin, Edna Chow Maneval, A. Craig Lockhart	7
18	Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial 2011 ·Annals of Oncology ·Amado J. Zurita, Daniel J. George, Neal D. Shore, (unknown), George Wilding, Thomas E. Hutson, Mark Kozloff, Paul Mathew, Charles S. Harmon, (unknown), I. Chen, Edna Chow Maneval, C. Logothetis	33
19	Sunitinib in combination with docetaxel and prednisone in patients (pts) with metastatic hormone-refractory prostate cancer (mHRPC) 2009 ·Journal of Clinical Oncology ·Amado J. Zurita, (unknown), Thomas E. Hutson, Mark Kozloff, Neal D. Shore, George Wilding, C. Logothetis, (unknown), Edna Chow Maneval, Daniel J. George	14
20	Distinct patterns of PSA modulation by single-agent sunitinib before combination with docetaxel and prednisone in patients with metastatic castrate-resistant prostate cancer (CRPCa) 2007 ·Journal of Clinical Oncology ·Amado J. Zurita, Neal D. Shore, Mark Kozloff, Chris Ryan, Tomasz M. Beer, Edna Chow Maneval, (unknown), C. Logothetis	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact